EORTC QLQ-C30 Reference Values

1 EORTC QLQ-C30 . Reference Values This manual presents Reference data for the QLQ-C30 based upon data provided by EORTC . Quality of Life Group Members and other users of the QLQ-C30 . July 2008. Neil W Scott, Peter M Fayers, Neil K Aaronson, Andrew Bottomley, Alexander de Graeff, Mogens Groenvold, Chad Gundy, Michael Koller, Morten A Petersen, Mirjam AG. Sprangers on behalf of the EORTC Quality of Life Group EORTC Quality of Life Group All rights reserved. No part of this manual covered by copyrights hereon may be reproduced or transmitted in any form or by any means without prior permission of the copyright holder. The EORTC QLQ-C30 (in all versions), and the modules which supplement it, are copyrighted and may not be used without prior written consent of the EORTC .

2 Headquarters. Requests for permission to use the EORTC QLQ-C30 or to reproduce or quote materials contained in this manual should be addressed to: Quality of Life Department, EORTC Headquarters, Avenue E Mounier 83 - B11, 1200 Brussels BELGIUM. Tel: +32 2 779 1678. Fax: +32 2 779 4568. This manual is based upon data contributed by members of the EORTC Groups, and by other users of the QLQ-C30 . It was prepared on behalf of the EORTC Quality of Life Group by: Neil W Scott 1, Peter M Fayers 1,2, Neil K Aaronson 3, Andrew Bottomley 4, Alexander de Graeff 5, Mogens Groenvold 6,7, Chad Gundy 3, Michael Koller 8, Morten A Petersen 6, Mirjam AG Sprangers 9. 1. Department of Public Health, University of Aberdeen, UK.

3 2. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway 3. Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands 4. Quality of Life Department, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium 5. Division of Medical Oncology, Department of Internal Medicine, University Medical Centre, Utrecht, Netherlands 6. Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark 7. Institute of Public Health, University of Copenhagen, Denmark 8. Centre for Clinical Studies, University Hospital Regensburg, Regensburg, Germany 9.

4 Department of Medical Psychology, Academic Medical Centre, University of Amsterdam, Netherlands i Members of the Quality of Life Cross-Cultural Meta-Analysis Group Australia: M King, S Leutenegger, N Spry; Austria: E Greimel, B Holzner; Belgium: C Coens, K. West; Brazil: G de Castro, C de Souza; Canada: A Bezjak, M Whitehead; Denmark: M Klee;. France: A Br dart, T Conroy, C Rodary; Germany: M Berend, B Bestmann, O Krau , T K chler, B. Malchow, R Schwarz, S Singer; Greece: K Mystakidou; Iran: A Montazeri; Italy: C Brunelli, M. Tamburini; Japan: T Matsuoka, H Zhao; Netherlands: R de Leeuw, M Muller; Norway: K Bjordal, E Brenne, M Hjermstad, M Jordh y, S Kaasa, P Klepstad, S Sundstr m, F Wisl ff; Singapore: YB.

5 Cheung, SB Tan, J Thumboo, HB Wong; South Korea: YH Yun; Spain: J Arraras; Sri Lanka: H. Jayasekara, L Rajapakse; Sweden: M Ahlner-Elmqvist; Switzerland: P Ballabeni, J Bernhard;. Taiwan: W-C Chie; Turkey: U Abacioglu; UK: J Blazeby, J Bruce, A Davies, L Friend, Z. Krukowski, T Massett, J Nicklin, J Ramage, A Smyth-Cull, T Young; USA: D Cella, D-L Esseltine, C Gotay, I Pagano. Contributing Groups European Organisation for Research and Treatment of Cancer ( EORTC ) Brain Group, EORTC . Breast Cancer Group, EORTC Chronotherapy Group, EORTC Gastro-Intestinal Group, EORTC . Genito-Urinary Group, EORTC Gynaecological Group, EORTC Head and Neck Group, EORTC . Leukaemia Group, EORTC Lung Group, EORTC Lymphoma Group, EORTC Melanoma Group, EORTC Quality of Life Group, EORTC Radiotherapy Group, EORTC Soft Tissue Group, National Cancer Institute Grant CA60068, National Cancer Institute of Canada (NCIC) Clinical Trials Group, Nordic Myeloma Study Group, Swiss Group for Clinical Cancer Research (SAKK).

6 Ii Contents Page Introduction and background 1. Why Reference data are important 2. Description of the tables 4. Sample size 6. References 11. EORTC QLQ-C30 Tables of Reference Values 14. All cancer patients: all stages 15. All cancer patients: males 19. All cancer patients: females 22. All cancer patients: <50 25. All cancer patients: 50-59 28. All cancer patients: 60-69 31. All cancer patients: >70 34. All cancer patients: stage I-II 37. All cancer patients: stage III-IV 40. All cancer patients: recurrent/metastatic 43. Brain cancer: all stages 46. Breast cancer: all stages 49. Breast cancer: <50 52. Breast cancer: 50-59 55. Breast cancer: 60-69 58. Breast cancer: >70 61. Breast cancer: stage I-II 64.

7 Breast cancer: stage III-IV 67. Breast cancer: recurrent/metastatic 70. Colorectal cancer: all stages 73. Colorectal cancer: males 76. Colorectal cancer: females 79. Colorectal cancer: <50 82. Colorectal cancer: 50-59 85. Colorectal cancer: 60-69 88. Colorectal cancer: >70 91. Colorectal cancer: stage I-II 94. Colorectal cancer: stage III-IV 97. Colorectal cancer: recurrent/metastatic 100. Genito-urinary cancer: all stages 103. Gynaecological cancer (cervical): all stages 106. Gynaecological cancer (ovarian): all stages 109. iii Gynaecological cancer (ovarian): stage I-II 112. Gynaecological cancer (ovarian): stage III-IV 115. Head and neck cancer: all stages 118. Head and neck cancer: males 121. Head and neck cancer: females 124.

8 Head and neck cancer: <50 127. Head and neck cancer: 50-59 130. Head and neck cancer: 60-69 133. Head and neck cancer: >70 136. Head and neck cancer: stage I-II 139. Head and neck cancer: stage III-IV 142. Head and neck cancer: hypopharynx/larynx 145. Head and neck cancer: oral cavity/oropharynx 148. Acute myelogenous leukaemia: all stages 151. Liver/bile/pancreas cancer: all stages 154. Lung cancer: all stages 157. Lung cancer: males 160. Lung cancer: females 163. Lung cancer: <50 166. Lung cancer: 50-59 169. Lung cancer: 60-69 172. Lung cancer: >70 175. Lung cancer: stage I-II 178. Lung cancer: stage III-IV 181. Lung cancer: recurrent/metastatic 184. Small cell lung cancer: all stages 187. Small cell lung cancer: limited disease 190.

9 Small cell lung cancer: extensive disease 193. Non-small cell lung cancer: all stages 196. Mesothelioma 199. Malignant lymphoma 202. Non-Hodgkin lymphoma 205. Malignant melanoma: all stages 208. Malignant melanoma: males 211. Malignant melanoma: females 214. Malignant melanoma: <50 217. Malignant melanoma: 50-59 220. Malignant melanoma: 60-69 223. Malignant melanoma: stage I-II 226. Malignant melanoma: stage III-IV 229. Malignant melanoma: recurrent/metastatic 231. Myeloma: all stages 232. Myeloma: stage I-II 238. Myeloma: stage III-IV 241. Oesophageal cancer: all stages 244. Oesophageal cancer: males 247. Oesophageal cancer: females 250. Oesophageal cancer: <50 253. iv Oesophageal cancer: 50-59 256. Oesophageal cancer: 60-69 259.

10 Oesophageal cancer: >70 262. Gastric cancer: all stages 265. Prostate cancer: all stages 268. Prostate cancer: 50-59 271. Prostate cancer: 60-69 274. Prostate cancer: >70 277. Prostate cancer: stage I-II 280. Prostate cancer: stage III-IV 283. Prostate cancer: recurrent/metastatic 286. Testicular cancer 289. General population 292. QLQ-C30 Module Data Breast module: all stages 295. Breast module: <50 299. Breast module: 50-59 301. Breast module: 60-69 304. Breast module: recurrent/metastatic 307. Head and neck module: all stages 310. Head and neck module: males 313. Head and neck module: females 316. Head and neck module: <50 319. Head and neck module: 50-59 322. Head and neck module: 60-69 325. Head and neck module: >70 328.